Lundbeck

39.44

DKK

-0.45 %

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Less than 1K followers

-0.45%

-4.55%

-5.42%

-18.17%

-1.55%

+9.56%

+21.43%

-25.89%

+60.33%

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Market cap

39.27B DKK

Turnover

680K DKK

Revenue

19.91B

EBIT %

16.05 %

P/E

17.07

Dividend yield-%

1.77 %

Financial calendar

5.2

2025

Annual report '24

26.3

2025

General meeting '25

14.5

2025

Interim report Q1'25

ShowingAll content types

Regulatory press release1/9/2025, 1:07 PM

H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD

Press release12/5/2024, 12:00 PM

H. Lundbeck A/S: Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Press release12/3/2024, 7:00 AM

H. Lundbeck A/S: Efficacy of Vyepti highlighted by new clinical trial results in severe migraine

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release12/2/2024, 2:08 PM

H. Lundbeck A/S: Lundbeck completes acquisition of Longboard

Regulatory press release11/28/2024, 6:56 AM

H. Lundbeck A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled

Press release11/27/2024, 7:00 AM

H. Lundbeck A/S: Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy

Regulatory press release11/13/2024, 6:29 AM

H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024

Regulatory press release10/31/2024, 11:44 AM

H. Lundbeck A/S: Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention

Press release10/23/2024, 7:01 AM

H. Lundbeck A/S: Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth

Regulatory press release10/14/2024, 10:30 AM

H. Lundbeck A/S: Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline

Press release10/3/2024, 7:00 AM

H. Lundbeck A/S: Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease

Press release9/27/2024, 12:00 PM

H. Lundbeck A/S: Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Press release9/26/2024, 10:00 AM

H. Lundbeck A/S: Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery

Regulatory press release8/20/2024, 7:09 AM

H. Lundbeck A/S: Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator

Regulatory press release8/20/2024, 6:53 AM

H. Lundbeck A/S: Lundbeck raises financial guidance for 2024

Press release7/31/2024, 6:00 AM

H. Lundbeck A/S: Lundbeck and Takeda modify the collaboration agreement for Trintellix in the U.S.

Regulatory press release6/25/2024, 5:59 AM

H. Lundbeck A/S: Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

Press release6/19/2024, 6:30 AM

H. Lundbeck A/S: Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing's disease trial

Press release6/3/2024, 12:00 PM

H. Lundbeck A/S: Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia

Regulatory press release5/15/2024, 5:31 AM

H. Lundbeck A/S: Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.